Bavarian Nordic eyes opportunities in huge pox vaccine stockpiles

Several countries are currently sitting on hundreds of millions of second-generation pox vaccines in case of biological terror attacks. But people do not accept the side effects, says the CEO of Bavarian Nordic, who wants to push the company’s pox vaccine into a leading position at these emergency stores.

Bavarian Nordic CEO Paul Chaplin | Photo: Bavarian Nordic /PR

Since 2007, the Strategic National Stockpile (SNS) has stockpiled enough pox vaccines to vaccinate every single person in the US if a biological terror attack occurs. The UK has done the same.

However, there is a problem with those vaccines. People don’t want them when they bring monkeypox home from countries where the virus is endemic, says Bavarian Nordic CEO Paul Chaplin.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs